天康生物(002100.SZ):擬引入兵團國資公司作為天康製藥新增國有資本股東
格隆匯6月1日丨天康生物(002100.SZ)公佈,為確保國有資本處於控股地位,在公司實施關於天康製藥(蘇州)有限公司(“天康製藥”)混合所有制及員工持股改革方案的同時,擬以非公開協議增資的方式引入新疆生產建設兵團國有資產經營有限責任公司(“兵團國資公司”)作為天康製藥新增國有資本股東,入股價格與引入的外部戰略投資者價格一致。
此次改革引進的員工持股、戰略投資者股東和國有資本股東的持股比例合計不超過公司混改完成後總股本的49%,其中:員工持股、戰略投資者股東不超過39%,國有資本股東不超過10%。兵團國資公司擬以自有資金向天康製藥協議增資(具體增資金額以天康製藥本次混合所有制改革完成後的實際金額為準),公司此次放棄對天康製藥的增資權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.